The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).
Despite numerous treatment advances, chronic hepatitis B virus (HBV) infection remains a largely incurable disease impacting more than 290 million people worldwide. All patients with chronic HBV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback